- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07849023
Application of Precision Partial Intersphincteric Resection (PPISR)
Application of Precision Partial Intersphincteric Resection (PPISR) in Patients With Ultra-low Rectal Cancer
The goal of this study is to establish a standardized operating procedure for Precision Partial Intersphincteric Resection (PPISR), and to evaluate its surgical safety, functional benefits, and oncological efficacy.
Study Overview
Status
Conditions
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: shaotang li
- Phone Number: 86+18815039766
- Email: lishaotang163@163.com
Study Locations
-
-
Zhejiang
-
Wenzhou, Zhejiang, China, 325000
- Recruiting
- First Affiliated Hospital of Wenzhou Medical University
-
Contact:
- chunwu zhang
- Phone Number: 86+0577-55578055
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients aged 18-75 years old
- Pathology suggestive of moderately to highly differentiated rectal adenocarcinoma
- Tumor lower margin ≤ 5 cm from the anal verge
- Pre-operative tumor (T) staging of T1-T3 and T1-T2 below the level of the anal raphe muscle
- No distant metastasis such as lung, liver and other organs
Exclusion Criteria:
- Preoperative patients with severe underlying diseases (such as severe liver and kidney function, cardiopulmonary function, coagulation dysfunction, etc.)
- Patients with malignant tumors in other parts of the body
- Patients who underwent emergency surgery due to acute perforation, obstruction, etc.
- Patients with tumor infiltration of peripheral organs during the operation, which required combined resection or palliative resection
- Patients who had a mid-opening laparoscopic operation for various reasons -during the operation
- Patients with poor anal function before operation, which is not suitable for anus preservation surgery.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: PPISR
The experimental group underwent the PPISR procedure. |
The experimental group underwent the PPISR procedure. The surgical process was as follows:
|
|
Active Comparator: Traditional ISR
The control group underwent the traditional ISR procedure |
The control group underwent the traditional ISR procedure. The surgical process was as follows:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Postoperative anal function as assessed by Wexner Score
Time Frame: At 3 and 6 months postoperatively
|
Scale Title: Wexner Fecal Incontinence Score. The minimum values:0. The maximum values:20. Higher scores mean a worse outcome. |
At 3 and 6 months postoperatively
|
|
Postoperative quality of life as assessed by EORTC QLQ-C30
Time Frame: At 1 year postoperatively
|
Scale Title: European Organization for Research and Treatment of cancer Quality of Life Questionnaire. The minimum values:0. The maximum values:100. Higher scores mean a worse outcome. |
At 1 year postoperatively
|
|
3-year local recurrence rate as assessed by abdominal contrast-enhanced MRI
Time Frame: 3 years postoperatively
|
Participants have an MRI every 3 months postoperatively |
3 years postoperatively
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Circumferential resection margin negative rate
Time Frame: Immediately after the pathology results come out
|
Immediately after the pathology results come out
|
|
|
intraoperative blood loss
Time Frame: Immediately after the surgery
|
Immediately after the surgery
|
|
|
Postoperative-related complication incidence
Time Frame: From the end of surgery to 3 months postoperatively
|
Complications include postoperative bleeding, abdominal cavity infection, thoracic cavity infection, urinary tract infection, etc. |
From the end of surgery to 3 months postoperatively
|
|
Postoperative hospital stay duration
Time Frame: From the end of surgery to discharge
|
From the end of surgery to discharge
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- KY2025-246
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.